Loading clinical trials...
Loading clinical trials...
A Phase Ib/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of CNCT19 in Children and Adolescent(Pediatric) Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
Conditions
Interventions
single dose of CNCT19
Locations
9
China
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Children's Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Guangzhou Women and Children's Medical Center
Guangzhou, Guangdong, China
Nanfang Hospital
Guangzhou, Guangdong, China
Union Hospital Tongji Medical College Huazhong University of Science of Technology
Wuhan, Hubei, China
Children's Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Start Date
February 7, 2023
Primary Completion Date
May 30, 2025
Completion Date
May 30, 2027
Last Updated
August 12, 2025
NCT07523555
NCT06395103
NCT07223021
NCT05674175
NCT07429461
NCT06785818
Lead Sponsor
Juventas Cell Therapy Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions